|
1
|
Gustafson S, Zbuk KM, Scacheri C and Eng
C: Cowden syndrome: Semin Oncol. 34:428–434. 2007.
|
|
2
|
Blumenthal GM and Dennis PA: PTEN
hamartoma tumor syndromes. Eur J Hum Genet. 16:1289–1300. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Feilotter HE, Nagai MA, Boag AH, Eng C and
Mulligan LM: Analysis of PTEN and the 10q23 region in primary
prostate carcinomas. Oncogene. 16:1743–1748. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cairns P, Okami K, Halachmi S, Halachmi N,
Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS and Sidransky D:
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cancer Res. 57:4997–5000. 1997.PubMed/NCBI
|
|
5
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
6
|
Ackler S, Ahmad S, Tobias C, Johnson MD
and Glazer RI: Delayed mammary gland involution in MMTV-AKT1
transgenic mice. Oncogene. 21:198–206. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bargonetti J and Manfredi JJ: Multiple
roles of the tumor suppressor p53. Curr Opin Oncol. 14:86–91. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Cristofano A, Pesce B, Cordon-Cardo C
and Pandolfi PP: Pten is essential for embryonic development and
tumor suppression. Nat Genet. 19:348–355. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Downward J: Mechanisms and consequences of
activation of protein kinase B/Akt. Curr Opin Cell Biol.
10:262–267. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mayo LD, Dixon JE, Durden DL, Tonks NK and
Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells
to chemotherapy. J Biol Chem. 277:5484–5489. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Z, Trotman LC, Shaffer D, Lin HK,
Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freeman DJ, Li AG, Wei G, Li HH, Kertesz
N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, et
al: PTEN tumor suppressor regulates p53 protein levels and activity
through phosphatase-dependent and -independent mechanisms. Cancer
Cell. 3:117–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lowe SW, Cepero E and Evan G: Intrinsic
tumor suppression. Nature. 432:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–43. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis
RT, Wu X, Stack EC, Loda M, Liu T, et al: EZH2 oncogenic activity
in castration-resistant prostate cancer cells is
polycomb-independent. Science. 338:1465–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu DC and Yang ZL: Overexpression of EZH2
and loss of expression of PTEN is associated with invasion,
metastasis and poor progression of gallbladder adenocarcinoma.
Pathol Res Pract. 207:472–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeng N, Yang KT, Bayan JA, He L, Aggarwal
R, Stiles JW, Hou X, Medina V, Abad D, Palian BM, et al: PTEN
controls β-cell regeneration in aged mice by regulating cell cycle
inhibitor p16ink4a. Aging Cell. 12:1000–1011. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vredeveld LC, Rowland BD, Douma S,
Bernards R and Peeper DS: Functional identification of LRF as an
oncogene that bypasses RASV12-induced senescence via upregulation
of CYCLIN E. Carcinogenesis. 31:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qu H, Qu D, Chen F, Zhang Z, Liu B and Liu
H: ZBTB7 overexpression contributes to malignancy in breast cancer.
Cancer Invest. 28:672–678. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao ZH, Wang SF, Yu L, Wang J, Chang H,
Yan WL, Zhang J and Fu K: Overexpression of Pokemon in non-small
cell lung cancer and foreshowing tumor biological behavior as well
as clinical results. Lung Cancer. 62:113–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aggarwal A, Hunter WJ III, Aggarwal H,
Silva ED, Davey MS, Murphy RF and Agrawal DK: Expression of
leukemia/lymphoma-related factor (LRF/POKEMON) in human breast
carcinoma and other cancers. Exp Mol Pathol. 89:140–148. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang G, Lunardi A, Zhang J, Chen Z, Ala U,
Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, et
al: Zbtb7a suppresses prostate cancer through repression of a
Sox9-dependent pathway for cellular senescence bypass and tumor
invasion. Nat Genet. 45:739–746. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
den Besten W, Kuo ML, Tago K, Williams RT
and Sherr CJ: Ubiquitination of and sumoylation by, the Arf tumor
suppressor. Isr Med Assoc J. 8:249–251. 2006.PubMed/NCBI
|
|
26
|
Bardeesy N, Aguirre AJ, Chu GC, Cheng KH,
Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, et
al: Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain
progression of pancreatic adenocarcinoma in the mouse. Proc Natl
Acad Sci USA. 103:5947–5952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ha L, Ichikawa T, Anver M, Dickins R, Lowe
S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya
EV and Merlino G: ARF functions as a melanoma tumor suppressor by
inducing p53-independent senescence. Proc Natl Acad Sci USA.
104:10968–10973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Z, Carracedo A, Lin HK, Koutcher JA,
Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W,
Teruya-Feldstein J, et al: Differential p53-independent outcomes of
p19(Arf) loss in oncogenesis. Sci Signal. 2:ra442009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Humbey O, Pimkina J, Zilfou JT, Jarnik M,
Dominguez-Brauer C, Burgess DJ, Eischen CM and Murphy ME: The ARF
tumor suppressor can promote the progression of some tumors. Cancer
Res. 68:9608–9613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khoo CM, Carrasco DR, Bosenberg MW, Paik
JH and Depinho RA: Ink4a/Arf tumor suppressor does not modulate the
degenerative conditions or tumor spectrum of the
telomerase-deficient mouse. Proc Natl Acad Sci USA. 104:3931–3936.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hajra KM, Chen DY and Fearon ER: The SLUG
zinc-finger protein represses E-cadherin in breast cancer. Cancer
Res. 62:1613–1618. 2002.PubMed/NCBI
|
|
32
|
Xie Y, Liu S, Lu W, Yang Q, Williams KD,
Binhazim AA, Carver BS, Matusik RJ and Chen Z: Slug regulates
E-cadherin repression via p19Arf in prostate tumorigenesis. Mol
Oncol. 8:1355–3564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Halvorsen OJ, Haukaas SA and Akslen LA:
Combined loss of PTEN and p27 expression is associated with tumor
cell proliferation by Ki-67 and increased risk of recurrent disease
in localized prostate cancer. Clin Cancer Res. 9:1474–1479.
2003.PubMed/NCBI
|
|
34
|
Liang J, Zubovitz J, Petrocelli T,
Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C,
Beniston R, et al: PKB/Akt phosphorylates p27, impairs nuclear
import of p27 and opposes p27-mediated G1 arrest. Nat Med.
8:1153–1160. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shin I, Yakes FM, Rojo F, Shin NY, Bakin
AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle
progression by phosphorylation of p27(Kip1) at threonine 157 and
modulation of its cellular localization. Nat Med. 8:1145–1152.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Viglietto G, Motti ML, Bruni P, Melillo
RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P,
Bellacosa A, et al: Cytoplasmic relocalization and inhibition of
the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated
phosphorylation in breast cancer. Nat Med. 8:1136–1144. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mullan PB, Quinn JE and Harkin DP: The
role of BRCA1 in transcriptional regulation and cell cycle control.
Oncogene. 25:5854–5863. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang H, Yang ES, Jiang J, Nowsheen S and
Xia F: DNA damage-induced cytotoxicity is dissociated from BRCA1′s
DNA repair function but is dependent on its cytosolic accumulation.
Cancer Res. 70:6258–6267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang J, Yang ES, Jiang G, Nowsheen S,
Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, et
al: p53-dependent BRCA1 nuclear export controls cellular
susceptibility to DNA damage. Cancer Res. 71:5546–5557. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nelson AC, Lyons TR, Young CD, Hansen KC,
Anderson SM and Holt JT: AKT regulates BRCA1 stability in response
to hormone signaling. Mol Cell Endocrinol. 319:129–142. 2010.
View Article : Google Scholar : PubMed/NCBI
|
